Cancer Screening Gaps Seen in Sexual, Gender Minority Groups

• by Andrea Surnit

• July 9, 2026

FDA approves hepcidin mimetic for PV

Phase 3 VERIFY results showed a 77% clinical response rate during weeks 20 to 32.

• by Kathryn Wighton

• August 31, 2026

• 3 min

FDA approves serial liquid biopsy testing

In SERENA-6, patients who changed treatment following detection of an ESR1 mutation had a 56% lower risk of disease progression or death.

• by Kathryn Wighton

• September 8, 2026

• 2 min

ACS report: Lung cancer deaths plunge as survival doubles

Lung cancer deaths fell by more than half among US males as smoking declined, earlier-stage diagnoses increased, and 5-year relative survival doubled.

• by Andrea Surnit

• September 28, 2026

• 6 min